Cite
Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial
MLA
Packer, Milton, et al. “Evaluation of the Effect of Sodium–glucose Co‐transporter 2 Inhibition with Empagliflozin on Morbidity and Mortality of Patients with Chronic Heart Failure and a Reduced Ejection Fraction: Rationale for and Design of the EMPEROR‐Reduced Trial.” European Journal of Heart Failure, vol. 21, no. 10, Oct. 2019, pp. 1270–78. EBSCOhost, https://doi.org/10.1002/ejhf.1536.
APA
Packer, M., Butler, J., Filippatos, G. S., Jamal, W., Salsali, A., Schnee, J., Kimura, K., Zeller, C., George, J., Brueckmann, M., Anker, S. D., Zannad, F., Filippatos, G., Perrone, S., Nicholls, S., Janssens, S., Bocchi, E., Giannetti, N., Verma, S., & Jian, Z. (2019). Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial. European Journal of Heart Failure, 21(10), 1270–1278. https://doi.org/10.1002/ejhf.1536
Chicago
Packer, Milton, Javed Butler, Gerasimos S. Filippatos, Waheed Jamal, Afshin Salsali, Janet Schnee, Karen Kimura, et al. 2019. “Evaluation of the Effect of Sodium–glucose Co‐transporter 2 Inhibition with Empagliflozin on Morbidity and Mortality of Patients with Chronic Heart Failure and a Reduced Ejection Fraction: Rationale for and Design of the EMPEROR‐Reduced Trial.” European Journal of Heart Failure 21 (10): 1270–78. doi:10.1002/ejhf.1536.